COVID Protection After Transplant-Immunosuppression Reduction (CPAT-ISR)
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
This study will enroll individuals who have:
- Completed primary series of mRNA COVID-19 vaccine, and
- An antibody response ≤ 2500 U/mL measured at least 30 days after the last dose of vaccine.
This group of patients is at high risk for severe COVID-19 disease due to pharmacologic immunosuppression and a high prevalence of non-transplant risk factors such as obesity and diabetes.
Full description
This study is a randomized, open-label multi-site trial designed to induce an enhanced antibody response to severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in kidney and liver transplant recipients who have ≤ 2500 U/mL anti-spike antibody (as measured by the Roche Elecsys® anti-SARS-CoV-2 S assay) after a completed primary series (3 doses) of mRNA COVID-19 vaccines.
Participants will be randomized to either:
- Receive a study dose of mRNA based COVID-19 vaccine (booster) with no change in their immunosuppressive regimen, or
- Undergo a temporary, prescribed reduction in their maintenance immunosuppression (IS) regimen and receive a study dose (booster) of mRNA based COVID-19 vaccine.
Protocol Version 8.0 will include a booster dose of either Pfizer-BioNTech COVID-19 Vaccine 2023-2024 or Moderna COVID-19 Vaccine 2023-2024, with or without IS reduction.
Duration of study participation for interested and eligible individuals: 13 months.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Individuals who meet all the following criteria are eligible for enrollment as study participants-
-
Able to understand and provide informed consent
-
Individual ≥18 years of age.
-
Recipient of a kidney or liver transplant ≥12 months prior to enrollment, without allograft rejection in the 6 months preceding enrollment
-
Negative for anti-donor human leukocyte antigens (HLA) antibodies at screening (Central Lab Test Determination).
-
Currently taking one of the following tacrolimus-based immunosuppressive regimens:
- Tacrolimus plus Mycophenolate Mofetil (MMF) or Mycophenolic Acid (MPA), with or without a corticosteroid
- Tacrolimus with trough ≥ 5ng/mL with or without ≤5 mg of prednisone or equivalent
-
Received a minimum of 3 doses of either the Moderna coronavirus infectious disease 19 (COVID-19) vaccine or Pfizer-BioNTech COVID-19 vaccine
-
Participant must be ≥ 60 days after completion of primary vaccination or receipt of the most recent booster dose with any authorized or approved monovalent or bivalent COVID-19 vaccine at the time of study vaccine.
-
Serum antibody negative or low (titer ≤ 2500 U/mL) at ≥ 30 days from the last dose of mRNA COVID-19 vaccine and ≥ 30 days following receipt of a monoclonal antibody product or convalescent plasma for COVID-19, measured using the Roche Elecsys® anti-SARS-CoV-2 S assay.
-
Participant's transplant physician or midlevel practitioner who is clinically licensed to prescribe and manage immunosuppression must confirm the participant's eligibility based on medical history.
Exclusion criteria
Individuals who meet any of these criteria are not eligible for enrollment as study participants-
-
Currently on an immunosuppressive regimen different from the three regimens described in the Inclusion Criteria, for example (but not limited to) those including sirolimus, everolimus, belatacept, or azathioprine
-
Recipient of any allograft other than a kidney or liver
-
Participant is pregnant
-
Any past history of Donor Specific Antibody (DSA) using local site standards
-
Prior receipt of the Moderna COVID-19 Vaccine 2023-2024 or Pfizer-BioNTech COVID-19 Vaccine 2023-2024.
-
Currently taking any systemic immunosuppressive agent, other than their prescribed transplant immunosuppression
-
Known history of severe allergic reaction to any component of an authorized or licensed COVID-19 vaccine
-
Thrombotic events, myocarditis, or pericarditis temporally associated with a prior dose of COVID-19 vaccine
-
History of heparin-induced thrombocytopenia
-
Any change in transplant immunosuppression regimen (drug or dose) in response to suspected or proven rejection within the last 6 months
-
More than minimal graft dysfunction, in accordance with study definition
-
Receipt of any cellular depleting agent (e.g. antithymocyte globulins (ATG), rituximab, alemtuzumab, Cyclophosphamide) within 12 months preceding enrollment
-
Concurrent autoimmune disease at risk for exacerbation with immunosuppression reduction
-
Any untreated active infection including BK viremia >10^4 copies
-
Infection with human immunodeficiency virus (HIV)
-
Recent (within one year) or ongoing treatment for malignancy with the exception of:
- Non- melanomatous skin cancer definitively treated by local therapy, and
- Definitively treated carcinoma-in-situ of the cervix (Stage 0 cervical cancer)
-
Treatment or prophylaxis of COVID-19 with a monoclonal antibody product or convalescent plasma within 6 months preceding enrollment, or
-
Any past or current medical problems, treatments, or findings which, in the opinion of the investigator, may:
- pose additional risks from participation in the study,
- interfere with the candidate's ability to comply with study requirements, or
- impact the quality or interpretation of the data obtained from the study.
Trial design
Primary purpose
Allocation
Interventional model
Masking
400 participants in 4 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal